Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;16(2):216-236.
doi: 10.1111/jebm.12539. Epub 2023 Jun 12.

Comparative analysis of systemic oncological treatments and best supportive care for advanced gastresophageal cancer: A comprehensive scoping review and evidence map

Santero Marilina  1 , Meade Adriana  1 , Selva Anna  1   2 , Acosta-Dighero Roberto  3 , Meza Nicolás  4 , Quintana Maria Jesús  1   5   6 , Bracchiglione Javier  1   4 , Requeijo Carolina  1 , Salazar Josefina  1 , Rodríguez Grijalva Gerardo  1 , Solà Ivan  1   5 , Urrútia Gerard  1   5 , Bonfill Cosp Xavier  1   5   6 ; Appropriateness of Systemic Oncological Treatments for Advanced Cancer (ASTAC) Research Group  1
Affiliations

Comparative analysis of systemic oncological treatments and best supportive care for advanced gastresophageal cancer: A comprehensive scoping review and evidence map

Santero Marilina et al. J Evid Based Med. 2023 Jun.

Abstract

Objective: To identify, describe, and organize the available evidence regarding systemic oncological treatments compared to best supportive care (BSC) for advanced gastresophageal cancer.

Methods: We conducted a thorough search across MEDLINE (PubMed), EMbase (Ovid), The Cochrane Library, Epistemonikos, PROSPERO, and Clinicaltrials.gov. Our inclusion criteria encompassed systematic reviews, randomized controlled trials, quasi-experimental and observational studies involving patients with advanced esophageal or gastric cancer receiving chemotherapy, immunotherapy or biological/targeted therapy compared to BSC. The outcomes included survival, quality of life, functional status, toxicity, and quality of end-of-life care.

Results: We included and mapped 72 studies, comprising SRs, experimental and observational designs, 12 on esophageal cancer, 51 on gastric cancer, and 10 both locations. Most compared schemes including chemotherapy (47 studies), but did not report therapeutic lines. Moreover, BSC as a control arm was poorly defined, including integral support and placebo. Data favor the use of systemic oncological treatments in survival outcomes and BSC in toxicity. Data for outcomes including quality of life, functional status, and quality of end-of-life care were limited. We found sundry evidence gaps specifically in assessing new treatments such as immunotherapy and important outcomes such as functional status, symptoms control, hospital admissions, and the quality of end-life care for all the treatments.

Conclusions: There are important evidence gaps regarding new for patients with advanced gastresophageal cancer and the effect of systemic oncological treatments on important patient-centered outcomes beyond survival. Future research should clearly describe the population included, specifying previous treatments and considering therapeutic, and consider all patient-centered outcomes. Otherwise, it will be complex to apply research results into practice.

Keywords: drug therapy; esophageal neoplasms; immunotherapy; molecular targeted therapy; review; stomach neoplasms.

PubMed Disclaimer

References

REFERENCES

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Can J Clin. 2021;71(3), 209-249.
    1. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19(34).
    1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3), 354-362.
    1. SEER*Explorer: An interactive website for SEER cancer statistics [Internet] [Internet]. Available from: https://seer.cancer.gov/explorer/
    1. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol. 2008;26(23), 3860-3866.

Publication types

MeSH terms

LinkOut - more resources